BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Krull KR" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Symptom burden, healthcare utilization, and risky behaviors in survivors of the childhood cancer survivor study (CCSS): an observation cohort study | Webster R; Srivastava DK; Xie L; Darji H; Liu W; McGrady ME; Brinkman TM; Alberts NM; Ness KK; Fuemmeler B; Kunin-Batson AS; Huang IC; Armstrong GT; Howell RM; Green DM; Yasui Y; Krull KR; | 41340862 PSYCHOLOGY |
| 2 | Intolerance of uncertainty, psychological symptoms, and pain in long-term childhood cancer survivors: a report from the Childhood Cancer Survivor Study | Alberts NM; Stratton KL; Leisenring WM; Pizzo A; Lamoureux É; Alschuler K; Flynn J; Krull KR; Jibb LA; Nathan PC; Olgin JE; Stinson JN; Armstrong GT; | 40699439 PSYCHOLOGY |
| 3 | Fear of Cancer Recurrence in Adult Survivors of Childhood Cancer | Pizzo A; Leisenring WM; Stratton KL; Lamoureux É; Flynn JS; Alschuler K; Krull KR; Jibb LA; Nathan PC; Olgin JE; Stinson JN; Armstrong GT; Alberts NM; | 39361286 PSYCHOLOGY |
| 4 | Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia | Partanen M; Alberts NM; Conklin HM; Krull KR; Pui CH; Anghelescu DA; Jacola LM; | 34813516 CONCORDIA |
| 5 | Change in Pain Status and Subsequent Opioid and Marijuana Use Among Long-Term Adult Survivors of Childhood Cancer. | Huang IC, Alberts NM, Buckley MG, Li Z, Ehrhardt MJ, Brinkman TM, Allen J, Krull KR, Klosky JL, Greene WL, Srivastava DK, Robison LL, Hudson MM, Anghelescu DL | 33409451 PSYCHOLOGY |
| 6 | Wearable Respiratory Monitoring and Feedback for Chronic Pain in Adult Survivors of Childhood Cancer: A Feasibility Randomized Controlled Trial From the Childhood Cancer Survivor Study. | Alberts NM, Leisenring WM, Flynn JS, Whitton J, Gibson TM, Jibb L, McDonald A, Ford J, Moraveji N, Dear BF, Krull KR, Robison LL, Stinson JN, Armstrong GT | 33147073 CONCORDIA |
| 7 | Pain in long-term survivors of childhood cancer: A systematic review of the current state of knowledge and a call to action from the Children's Oncology Group. | Schulte FSM, Patton M, Alberts NM, Kunin-Batson A, Olson-Bullis BA, Forbes C, Russell KB, Neville A, Heathcote LC, Karlson CW, Racine NM, Charnock C, Hocking MC, Banerjee P, Tutelman PR, Noel M, Krull KR | 33112416 PSYCHOLOGY |
| Title: | Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia | ||||
| Authors: | Partanen M, Alberts NM, Conklin HM, Krull KR, Pui CH, Anghelescu DA, Jacola LM | ||||
| Link: | pubmed.ncbi.nlm.nih.gov/34813516/ | ||||
| DOI: | 10.1097/j.pain.0000000000002485 | ||||
| Publication: | Pain | ||||
| Keywords: | |||||
| PMID: | 34813516 | Category: | Date Added: | 2021-11-23 | |
| Dept Affiliation: |
CONCORDIA
1 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands Concordia University, Montréal, QC, Canada St. Jude Children's Research Hospital, Memphis, TN, United States. |
||||
Description: |
Children with acute lymphoblastic leukemia (ALL) often experience treatment-related neurocognitive deficits and significant pain. Pain may exacerbate these cognitive impairments. This study examined neuropathic pain and neurocognitive outcomes in survivors of childhood ALL treated with contemporary therapy on a clinical trial (<a href="http: clinicaltrials.gov/show/NCT00137111" title="See in ClinicalTrials.gov">NCT00137111</a>). There were 345 survivors (45% female, M = 6.9 years at diagnosis) who completed neurocognitive assessments including measures of sustained attention, learning and memory, and parent ratings of attention during at least one of 4 time points: on-therapy (Induction and Reinduction), end of therapy, and 2 years post-therapy. At-risk performance was defined as a score at least 1SD below the age-adjusted mean. Data on neuropathic pain (events, duration, and severity according NCI Common Toxicity Criteria) and pharmacologic pain management (opioids and gabapentin) were ascertained. Results showed that 135 survivors (39%) experienced neuropathic pain during treatment. Compared with those without pain, survivors with pain had greater memory impairments at end of therapy (California Verbal Learning Test [CVLT]-Total, 24% vs 12%, P = 0.046). Within the pain group, survivors who experienced a greater number of pain events (CVLT-Total = -0.88, P = 0.023) and those who were treated with opioids (versus gabapentin) had poorer learning and memory performance (CVLT-Total = -0.73, P = 0.011; Short Delay = -0.57, P = 0.024; Long Delay = -0.62, P = 0.012; and Learning Slope = -0.45, P = 0.042) across time points. These are considered medium-to-large effects (SD = 0.45-0.88). Neuropathic pain may be a risk factor for learning problems after therapy completion, and treatment for pain with opioids may also adversely affect neurocognitive performance. Therefore, patients who experience pain may require closer monitoring and additional intervention for neurocognitive impairment. |
